Axsome Therapeutics Highlights Auvelity Momentum, 600-Rep Sales Push, and April 30 ADA PDUFA at Oppenheimer Conf. [Yahoo! Finance]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Yahoo! Finance
Axsome Therapeutics logo Key Points Auvelity commercial momentum: Axsome is expanding its U.S. sales force from ~300 to a planned 600 reps to drive primary-care penetration, reports roughly 86% total covered lives, and cites GTN of ~high-40% in Q4 (mid-50% in Q1 seasonally). PDUFA and ADA opportunity: The supplemental NDA for Auvelity in Alzheimer's disease agitation is on FDA priority review with a PDUFA date of April 30 , supported by four controlled trials (three positive) and an ICH safety database, and management expects the market to be largely Medicare Part D with potentially better GTN per script. Pipeline and finance: solriamfetol has a Phase 3 BED topline expected in the second half of the year and other expansion readouts scheduled over the next year, AXS-12 NDA is imminent, and the company says the sales-force build accelerates commercial investment while maintaining guidance and a near-term path to cash-flow and EPS positivity. Interested in Axsome Therapeutics
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Axsome Therapeutics (AXSM) was upgraded by Wolfe Research to "strong-buy".MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) was given a new $207.00 price target on by analysts at Morgan Stanley.MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
AXSM
Earnings
- 2/23/26 - Beat
AXSM
Sec Filings
- 2/25/26 - Form 4
- 2/23/26 - Form 4
- 2/23/26 - Form 10-K
- AXSM's page on the SEC website